Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 1,089 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) CFO Charles N. York II sold 1,089 shares of the stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $24.31, for a total value of $26,473.59. Following the completion of the transaction, the chief financial officer now owns 324,401 shares in the company, valued at $7,886,188.31. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN traded down $0.17 during midday trading on Wednesday, hitting $24.07. The stock had a trading volume of 820,120 shares, compared to its average volume of 834,740. The company has a 50 day simple moving average of $18.26 and a two-hundred day simple moving average of $13.24. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.44 and a twelve month high of $28.70.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.11). Equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently modified their holdings of the stock. FMR LLC grew its holdings in Day One Biopharmaceuticals by 163.1% during the second quarter. FMR LLC now owns 6,826,574 shares of the company’s stock worth $122,196,000 after purchasing an additional 4,232,055 shares during the period. Deerfield Management Company L.P. Series C grew its holdings in Day One Biopharmaceuticals by 68.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company’s stock worth $62,867,000 after purchasing an additional 1,425,674 shares during the period. RA Capital Management L.P. boosted its holdings in shares of Day One Biopharmaceuticals by 22.0% during the first quarter. RA Capital Management L.P. now owns 6,060,090 shares of the company’s stock worth $60,116,000 after acquiring an additional 1,094,502 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 59.8% during the second quarter. Franklin Resources Inc. now owns 2,465,380 shares of the company’s stock worth $44,130,000 after acquiring an additional 922,521 shares during the period. Finally, Atlas Venture Life Science Advisors LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9.3% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company’s stock worth $160,533,000 after acquiring an additional 766,667 shares during the period. Institutional investors own 79.02% of the company’s stock.

Wall Street Analyst Weigh In

DAWN has been the topic of several recent research reports. Piper Sandler raised their price target on Day One Biopharmaceuticals from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, June 20th. Wedbush raised their price target on Day One Biopharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, June 13th.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Stories

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.